The need for dedicated DAPT updates is well justified by the large amount of data and new information generated in the field over the past few years.
As expected, the ACC/AHA and ESC updates contain large areas of overlap as well as some differences. From a methodological standpoint, the 2016 ACC/ AHA update was built around 3 critical questions related to the duration of DAPT, which served as the basis for a formal systematic review and evaluation of the available data (6) . The writing group consisted of the chairs, vice-chairs, and members of previous guidelines tackling the topic of DAPT. Conversely, the 2017 ESC update was built in keeping with recommendations for formulating and issuing ESC guidelines by a selection of experts in the field, based on a comprehensive review of the published evidence (7) . This paper aims to review and compare the ACC/ AHA and ESC updates for DAPT to delineate common domains, consistent messages, and differences in recommended management strategies across the Atlantic. Meanings and suggested phrasings of Class of Recommendation (COR) and Level of Evidence (LOE) for each update are summarized in Tables 1   and 2 . While the interpretation of the COR I and III is straightforward, the COR IIa and IIb imply conflicting evidence or divergence of opinion regarding the relative benefit and risk of a given treatment or procedure. In general, when the COR is IIa, the weight of the evidence or opinion is in favor of the treatment or procedure, whereas a COR IIb implies that there is not enough data to make a more definitive recommendation, the data may be somewhat contradictory, or the benefit may be extremely modest. Notably, despite some subtle differences that exist in criteria for and phrasing of COR and LOE in the ACC/AHA and ESC updates, the general meaning is essentially consistent. Common themes in both the ACC/AHA and ESC focused updates include risk stratification, the type and initial timing of P2Y 12 inhibitor administration, the duration of DAPT in different patient scenarios, the use of proton pump inhibitors, and the management of antiplatelet therapy in patients on oral anticoagulation (6, 7) . Some areas of controversy (e.g., drug-to-drug interactions, platelet function and genetic testing, bridging of antiplatelet agents in the perioperative period, and dual-pathway inhibition therapy with both antiplatelet and anticoagulant agents) are either not addressed or only briefly discussed due to lack of conclusive data supporting specific recommendations. although it is recognized that many patients are at high risk for both types of event (6, 7) . In both documents, the DAPT score, derived from the DAPT trial (9) , is discussed as a way to assess the risk/benefit of prolonging DAPT beyond 12 months from PCI, based on the contribution of a number of risk factors (10) .
GENERAL CONCEPTS
The prediction rule assigns positive integer values to diabetes mellitus, current cigarette use, prior PCI or prior MI, congestive heart failure or left ventricular Capodanno et al. Capodanno et al. The 2016 ACC/AHA update does not mention LOE for these recommendations, which were "C" in previous guideline for PCI (32) . Conversely, in the ESC document, the use of a proton pump inhibitor while on DAPT is COR I, LOE B, with no further distinctions (7) based on an in-depth assessment of patient selection criteria and results of a large trial (31) .
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RECOMMENDATIONS ON DAPT DURATION
Recommendations on DAPT duration play a major part in the ACC/AHA and ESC focused updates and are discussed in the following paragraphs (6, 7) . For each clinical scenario, an evidence summary is provided, followed by a description of specific recommendations (Central Illustration, Figure 4 ). Capodanno et al. Figure 1 .
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PATIENTS WITH PRIOR MI. In the PEGASUS-TIMI 54 trial, 2 doses of ticagrelor (60 and 90 mg twice daily)
were studied, and both decreased the incidence of ischemic events in 21,162 patients with a history of prior MI from 1 to 3 years earlier, but also both increased the incidence of major bleeding (55 Abbreviations as in Table 1 .
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PLATO trial for ticagrelor (12) . Among these studies,
TRILOGY ACS included only ACS patients with no
invasive management, and they were not found to derive a significant ischemic benefit from prasugrel compared with clopidogrel (57) . 
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therapy, goes beyond the scope of this section and is described elsewhere (65, 66) . Proton pump inhibitors Class I in patients on DAPT with a history of gastrointestinal bleeding and those at increased risk of gastrointestinal bleeding.
Class I in patients on DAPT.
DAPT duration after PCI for stable coronary artery disease
Default DAPT duration is 6 months after drug-eluting stent and 1 month after bare-metal stent implantation.
Default DAPT duration is 6 months regardless of stent type. A 1-month course of DAPT may be considered in selected patients treated with drug-eluting stents and at high bleeding risk.
DAPT duration after PCI for ACS Extended therapy recommended as Class IIb for selected patients at low bleeding risk.
Extended therapy, preferentially with ticagrelor, recommended as Class IIb for selected patients with prior myocardial infarction.
DAPT duration in patients undergoing CABG
Does not include updated recommendations or revision of existing recommendations from previous guidelines.
Includes an updated dedicated section.
DAPT duration in patients with ACS medically managed
Class IIa for ticagrelor in preference to clopidogrel for 12 months.
Class I for ticagrelor in preference to clopidogrel for 12 months.
DAPT in patients undergoing noncardiac surgery Surgery must be delayed 1 month after implantation of bare-metal stents and 6 months after implantation of DES (Class I).
Surgery should occur no sooner than 1 month irrespective of the stent type (Class IIa) and no sooner than 6 months in case of recent MI or other high ischemic risk features (Class IIb). Option for bridging strategy with intravenous antiplatelet agents in selected patients (Class IIb).
Antiplatelet therapy in patients on oral anticoagulation
Includes an updated dedicated section. Overall, dual therapy was noninferior to triple therapy with respect to the risk of thromboembolic events. Other ongoing studies testing antithrombotic strategies in atrial fibrillation patients undergoing PCI, including strategies with the use of apixaban (88) and edoxaban (89) , are currently ongoing. 
